Industry: Pharmaceuticals, Biotechnology
Theregen, Inc. (formerly Iken Tissue Therapeutics) is a regenerative medicine company that develops cell-based therapies for patients with cardiovascular and vascular disease. Theregen has worldwide exclusive rights to research, manufacture, develop and commercialize its lead product, Anginera,, for cardiovascular and vascular applications. The company is conducting a Phase I human clinical safety trial for Anginera, a cell-based epicardial therapy. Anginera has been shown in animal models to have the potential to induce remodeling and angiogenesis in the ischemic heart, leading to functional changes that may benefit patients with heart ( www.theregeninc.com )
Theregen Corporation
225 Bush St. 16Th Flr.
San Francisco, California 94104
USA
Tel: (415) 439-8320
Fax: (415) 439-8322